Registry Launched for Hemophilia A Patients
- By BSTQ Staff
Grifols has launched the SPIRIT (Study of Plasma-derived factor VIII/VWF in Immune toleRance Induction Therapy) registry for patients with hemophilia A. The registry will enroll U.S. patients with hemophilia A and inhibitors being treated with Grifols’ plasma-derived factor VIII/VWF product, Alphanate (antihemophilic factor/von Willebrand factor complex [human]). According to the registry’s lead investigator, Rebecca Kruse-Jarres, MD, of Tulane University, this observational study fills an important void. “There is not a lot of prospective data to help us understand how patients with inhibitors respond to treatment, especially as it relates to adherence and quality of life,” she explains. “The data from the SPIRIT registry will give us more information to treat our patients and should complement the ongoing RESIST study.” RESIST is an international immune tolerance induction study in patients who have already experienced a failure with a VWF-free FVIII concentrate.
